--- title: "Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities | GENFF Stock News" description: "Genflow Biosciences PLC has received administrative approval for €4 million in funding from the Wallonia Region to support the development of its gene therapy candidate GF-1002 for treating Metabolic " type: "news" locale: "en" url: "https://longbridge.com/en/news/273947095.md" published_at: "2026-01-27T23:00:00.000Z" --- # Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities | GENFF Stock News > Genflow Biosciences PLC has received administrative approval for €4 million in funding from the Wallonia Region to support the development of its gene therapy candidate GF-1002 for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). The funding is expected to be disbursed by May 2026 and aligns with the company's 2026 development priorities, focusing on capital efficiency and early-stage collaborations. CEO Dr. Eric Leire emphasized the importance of this funding in advancing their pipeline and maintaining a data-driven approach. **THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.** **Genflow Biosciences Plc** **Administrative Approval of €4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities** Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately €4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont. The funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis ("MASH"). The original RNS announcing the award can be found here. Disbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme. **Development Priorities for 2026** In 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, provide external validation of the platform, and support continued development. With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation. **Dog Aging (GF-1004)** The ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. An initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects. **Glaucoma Programme** The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisation (CRO) to manage RNA-based formulation activities through preclinical execution. **Additional Programmes** Across the broader pipeline, Genflow continues to advance its sarcopenia programme in line with established development plans. In parallel, the ExoFastTrack initiative continues to generate data intended to support and accelerate multiple programmes across the portfolio. Dr. Eric Leire, CEO of Genflow, commented: "The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus. It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline. As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation." **Contacts** **Genflow Biosciences** **Harbor Access** Dr Eric Leire, CEO Jonathan Paterson, Investor Relations +32-477-495-881 +1 475 477 9401 Jonathan.Paterson@Harbor-access.com **About Genflow Biosciences** Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X. **DISCLAIMER** The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions. Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. **SOURCE:** Genflow Biosciences PLC View the original press release on ACCESS Newswire ### Related Stocks - [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md) - [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md) - [PJP.US - Invesco Pharmaceuticals ETF](https://longbridge.com/en/quote/PJP.US.md) - [XPH.US - SPDR Pharmac](https://longbridge.com/en/quote/XPH.US.md) - [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md) - [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md) - [159938.CN - GF CSI All Share Health Care ETF](https://longbridge.com/en/quote/159938.CN.md) - [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md) - [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md) - [PPH.US - VanEck Pharmaceutical ETF](https://longbridge.com/en/quote/PPH.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Haleon 2025 財年的利潤上升，但收入下降；預計 2026 財年及中期將實現增長；計劃進行 5 億英鎊的股票回購 | Haleon plc 報告稱，儘管收入下降 1.8% 至 110.3 億英鎊，但 FY25 税前利潤仍增長 12.7%，達到 21.5 億英鎊。公司預計 FY26 的有機收入增長為 3-5%，調整後的營業利潤增長為高個位數。此外，Haleo | [Link](https://longbridge.com/en/news/276853630.md) | | Sensodyne 的製造商 Haleon 預測，由於美國市場需求疲軟，2026 年的增長將低於預期目標 | Haleon，Sensodyne 的製造商，預測 2026 年的有機收入增長為 3% 至 5%，低於其目標，原因是美國需求疲軟。該公司在第四季度報告了 2.1% 的有機收入增長，受到温和的感冒和流感季節的影響。美國消費者支出仍然疲軟，影響了 | [Link](https://longbridge.com/en/news/276871112.md) | | ETMESCIUS USA, Inc. 發佈了 ActiveReports.NET v20 | MESCIUS USA Inc. 宣佈發佈 ActiveReports.NET v20，針對開發人員創建動態報告的效率進行了增強。主要功能包括智能數據區域，以快速生成報告，以及 AI 圖像到報告功能，將靜態圖像轉換為可編輯佈局。更新後的基於 | [Link](https://longbridge.com/en/news/277037715.md) | | Amneal Pharmaceuticals 的盈利前景展望 | Amneal Pharmaceuticals（納斯達克代碼：AMRX）定於 2026 年 2 月 27 日發佈季度財報，分析師預計每股收益（EPS）為 0.18 美元。該公司此前超出每股收益預期 0.04 美元，導致股價上漲 8.2%。目前 | [Link](https://longbridge.com/en/news/277054476.md) | | Eton Pharmaceuticals 報告稱，美國 FDA 已批准 Desmoda 口服溶液 | 2026 年 2 月 25 日下午 2:59（東部標準時間）——Eton Pharmaceuticals（ETON）週三表示，美國食品藥品監督管理局已批准 Desmoda 液體口服溶液用於所有年齡患者的中央性尿崩症管理。Eton 表示，商業 | [Link](https://longbridge.com/en/news/276932772.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.